Supernus Pharmaceuticals, Inc. Being Investigated on Behalf of Supernus Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details.
Portfolio Pulse from
Supernus Pharmaceuticals, Inc. is under investigation by Levi & Korsinsky for potential federal securities law violations after its Phase 2b study of SPN-820 for treatment-resistant depression failed to meet its primary endpoint.
February 26, 2025 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Supernus Pharmaceuticals is being investigated for potential securities law violations after its SPN-820 study failed to meet primary endpoints.
The investigation by Levi & Korsinsky and the failure of the SPN-820 study are likely to negatively impact Supernus Pharmaceuticals' stock price in the short term due to potential legal issues and the setback in drug development.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100